Gregory D. Kirk, MD
Center & Institute Affiliation(s):
615 N Wolfe St.
Baltimore , Maryland
MD , University of Oklahoma , 1993
PhD , Johns Hopkins University
MPH , Johns Hopkins University
My research focuses on understanding the natural history of viral infections, particularly HIV and the hepatitis viruses, in both domestic and international settings. The ALIVE (AIDS Linked to the Intravenous Experience) study is a long-standing and productive cohort that characterizes the natural history of HIV infection among intravenous drug users in Baltimore, MD. Our research in ALIVE ranges from pathogenesis to clinical to behavioral. In particular, I focus on the non-AIDS outcomes of HIV including cancer, liver and lung diseases. I also work on related topics with international collaborators, primarily in Africa. The interaction of viral, environmental and genetic factors is an important determinant in progression of many viral diseases. My research employs genetic, proteomic, and other novel laboratory and imaging methods to help understand and identify individuals at greatest risk for clinically relevant outcomes from HIV, HBV and HCV infections. The long-term goal of this research is to translate these markers into targeted interventions to help reduce the burden from these infections.
Honors and Awards
1994-1997, American Cancer Society, Physician Training Award in Preventive Medicine
1995, Delta Omega National Public Health Honor Society
1996, AMA Glaxo-Wellcome Resident Leadership Award for Outstanding Community Service
1997, Fellowship for Research Training in Cancer, International Agency for Research on Cancer
1998, Visiting Scientist, International Agency for Research on Cancer
2002, American Society of Microbiology, George McCracken Infectious Disease Fellow Award
2002, NIH Fellow’s Award for Research Excellence
2003, Phi Beta Kappa, JHBSPH
hepatitis B virus, HBV;hepatitis C virus, HCV; HIV / AIDS; HAART; non-AIDS outcomes (lung, liver disease); drug use; epidemiology; liver cancer; biomarkers; proteomics; genetic susceptibility; ALIVE study; The Gambia; Uganda;
Selected Recent Publications
Stabinski L†, Reynolds S, Ocama P, Laeyendecker O, Ndyanabo A, Kiggundu V, Boaz I, Gray RH, Wawer M, Thio CL, Thomas DL, Quinn TC, Kirk GD. High prevalence of liver fibrosis associated with HIV infection: A study in rural Rakai, Uganda. Antiviral Therapy, 2011 (In Press)
Stabinski L†, Reynolds S, Ocama P, Laeyendecker O, Serwadda D, Gray RH, Wawer M, Thomas DL, Quinn TC, Kirk GD. Hepatitis B virus and sexual behaviour in Rakai, Uganda. J Med Virol, 2011 (In Press)
Kirk GD, Merlo C. HIV infection in the etiology of lung cancer: Confounding, causality and consequences. Proc Am Thoracic Soc, 2011 (In Press).
Genberg B, Gange S, Go V, Celentano D, Kirk GD, Mehta SH. Trajectories of injection drug use over 20 years (1988-2008) in Baltimore, Maryland. Am J Epi, 2011 (In Press).